Conor Steuer, MD
Hematology & Oncology · Atlanta, GANPI 1386888220
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $66,368 of the $86,093 with a category attached, or 77.1%. 18 manufacturers reported payments, led by Novocure Inc. at 26.4% of the total. Among hematology & oncology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 74 payments — averaging $1163.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$23K
- Daiichi Sankyo Inc.$9K
- Regeneron$7K
- Boehringer Ingelheim International GmbH$7K
- Sanofi$6K
- Lilly USA, LLC$5K
- plus $28K from 12 others
Across 792 payments — averaging $5473.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$1.6M
- Merck$740K
- AstraZeneca$625K
- Novartis$404K
- Eli Lilly$383K
- Genmab U.S., Inc.$231K
- plus $370K from 10 others
What the payments were for
- Consulting fees$66,36877%
- Speaking & faculty fees$15,10618%
- Travel & lodging$2,9953%
- Food & beverage$1,6032%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 26 | $22,736 |
| Daiichi Sankyo Inc. | 8 | $9,351 |
| Regeneron | 2 | $7,479 |
| Boehringer Ingelheim International GmbH | 4 | $7,400 |
| Sanofi | 2 | $6,197 |
| Lilly USA, LLC | 7 | $5,310 |
| Regeneron Healthcare Solutions, Inc. | 3 | $5,289 |
| G1 Therapeutics, Inc. | 2 | $3,617 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,925 |
| AstraZeneca | 8 | $2,851 |
| Coherus Oncology, Inc. | 2 | $2,388 |
| Boehringer Ingelheim | 1 | $2,220 |
| Novartis | 1 | $2,025 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,920 |
| Merck | 1 | $1,830 |
| F. Hoffmann-la Roche AG | 2 | $1,476 |
| Bayer | 1 | $1,028 |
| Mirati Therapeutics, Inc. | 2 | $51 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$18,964
- OPTUNE LUA (NOVOTTF-200T)$13,806
- COSELA$3,617
- ALUNBRIG$2,925
- LOQTORZI$2,388
- TABRECTA$2,025
- Non-Covered Product$1,476
- Vitrakvi$1,028
- IMFINZI$683
- ALIMTA$417
How this compares
$86,093 in reported general payments places this provider in the 90th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 74 | $1,208,179 |
| MekinistTrametinib Dimethyl Sulfoxide | 28 | $428,926 |
| TafinlarDabrafenib Mesylate | 28 | $385,299 |
| LorbrenaLorlatinib | 18 | $368,408 |
| LenvimaLenvatinib Mesylate | 11 | $248,400 |
| AlecensaAlectinib Hcl | 11 | $168,057 |
| EliquisApixaban | 34 | $22,256 |
| XareltoRivaroxaban | 11 | $8,444 |
| Erlotinib Hcl | 26 | $6,608 |
| Oxycodone Hcl | 81 | $801 |
| Dexamethasone | 140 | $620 |
| Ondansetron Hcl | 93 | $591 |
| Prochlorperazine Maleate | 98 | $549 |
| Lidocaine Hcl ViscousLidocaine Hcl | 11 | $208 |
| Ondansetron OdtOndansetron | 11 | $96 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $2,851 | $1,208,17974 claims |
| NovartisMekinist, Tafinlar | $2,025 | $814,22556 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Atlanta
- Ticiana LealAtlanta$450K
- Ajay NookaAtlanta$222K
- Rodolfo BordoniAtlanta$159K
- Mehmet BilenAtlanta$150K
- Olatunji AleseAtlanta$137K
- Gina D AmatoAtlanta$97K
- Otis BrawleyAtlanta$89K
- Fuad El RassiAtlanta$84K
- Jonathon CohenAtlanta$84K
- Ioana BontaAtlanta$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.